ARTICLE | Clinical News
Alnylam preclinical data
January 6, 2014 8:00 AM UTC
In a mouse model of obesity and mixed hyperlipidemia, subcutaneous doses of 3 mg/kg ALN-ANG reduced triglyceride levels from baseline by >=95%, LDL-C levels by >=85% and total cholesterol by >=60%. Da...